You are viewing: Rest Of Latin America Gene Editing Market analysis
Part of: Gene Editing Market (Global)

The Rest Of Latin America Gene Editing Market was valued at $34.4 Million in 2024 and projected to reach to $50.6 Million by 2029, representing a compound annual growth rate of 8.0%. Rest Of Latin America's gene editing market is poised for steady expansion, driven by increasing healthcare infrastructure investments and growing awareness of genetic therapy applications.

Rest Of Latin America Gene Editing Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Latin America Gene Editing Market Trends and Insights

  • This 8.0% compound annual growth rate reflects increasing adoption of advanced genetic therapies and rising healthcare investments across the region.
  • Rest Of Latin America is positioning itself as an emerging hub for gene editing applications, driven by improving regulatory frameworks and growing collaboration with international research institutions. The gene editing landscape in Rest Of Latin America is characterized by expanding clinical research initiatives and growing pharmaceutical interest in genetic disease treatment.
  • Rest Of Latin America's market growth is supported by rising prevalence of genetic disorders, increased healthcare spending, and strengthening biotechnology infrastructure.
  • Between 2024 and 2029, Rest Of Latin America is expected to witness accelerated adoption of CRISPR and other gene-editing technologies, particularly in therapeutic applications targeting inherited diseases and cancer treatment. Rest Of Latin America's competitive environment is becoming increasingly dynamic, with both regional players and international companies establishing presence to capitalize on market opportunities.
  • Rest Of Latin America's trajectory demonstrates the region's commitment to advancing precision medicine and genomic healthcare solutions..

Key Market Statistics

  • CAGR (2024-2029) 8.0% CAGR
  • Market Size, 2024 ~USD 34.4 Million
  • Forecast, 2029 ~USD 50.6 Million
  • Country Rest Of Latin America

Rest Of Latin America Gene Editing Market Overview

Market Valuation Growth :

Rest Of Latin America's gene editing market is valued at $34.4 million in 2024, with projections reaching $50.6 million by 2029, representing a robust 8% CAGR over the forecast period.

Healthcare Investment Surge :

Rising healthcare investments across Rest Of Latin America are driving adoption of advanced genetic therapies, positioning the region as an emerging hub for gene editing applications and clinical implementations.

Emerging Market Potential :

Rest Of Latin America demonstrates significant untapped potential compared to global growth rates, with an 8% CAGR indicating steady market maturation and increasing accessibility to gene editing technologies.

Therapeutic Adoption Acceleration :

Growing recognition of gene editing's therapeutic benefits in treating genetic disorders is accelerating adoption rates across Rest Of Latin America's healthcare systems and research institutions.

Rest Of Latin America Gene Editing Market Dynamics

  • The region's 8% CAGR reflects a measured but consistent adoption trajectory as healthcare providers and research institutions integrate advanced gene editing technologies into their therapeutic portfolios. Looking ahead to 2029, Rest Of Latin America will benefit from improved regulatory frameworks, enhanced funding mechanisms, and collaborative partnerships with global biotech leaders.
  • This growth trajectory positions the region as an attractive market for gene editing companies seeking to expand their Latin American presence while addressing unmet medical needs in genetic disorder treatment..

Market Ecosystem

logo-mobile

GENE EDITING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Collaborates with Beam Therapeutics to develop in vivo base editing therapies targeting rare genetic diseases affecting the liver, muscles, and central nervous system. The programs utilize precision genome editing and lipid nanoparticle-based delivery technologies. Supports the development of targeted genetic medicines, enables precise modification of disease-associated DNA sequences, and advances research into potential treatments for inherited disorders.
company logo
Supports genome editing research through its Somatic Cell Genome Editing (SCGE) program, focusing on CRISPR-based technologies, targeted delivery systems, genome editing efficiency, and safety evaluation for therapeutic applications. Accelerates the development of genome editing tools, improves editing specificity and delivery efficiency, supports off-target analysis, and advances research into potential gene editing therapies for genetic diseases.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Key Takeaways

  • Rest Of Latin America's gene editing market is valued at $34.4 million in 2024 and is forecast to reach $50.6 million by 2029, representing an 8.0% CAGR.
  • Rest Of Latin America is experiencing increased adoption of CRISPR and advanced gene-editing technologies driven by rising genetic disorder prevalence and healthcare investment.
  • Rest Of Latin America's market growth is supported by improving regulatory frameworks and strengthening biotechnology infrastructure across the region.
  • Rest Of Latin America's competitive landscape is becoming increasingly dynamic with both regional and international players establishing market presence.

Gene Editing Market Report Scope

Report Metric Details
Base Year 2024
Fastest Growing Segment CROS & CDMOS (End User)
Forecast Period 2024–2029
Growth Rate CAGR of 10.2% from 2024 to 2029
Largest Segment PRODUCTS (Offering)
Market Size Base Year (Billions) ~USD 4.67 (2024)
Revenue Forecast (Billions) ~USD 7.59 (2029)
Segments Covered Offering, Type, Technique, Technology, Application, End User

Rest Of Latin America Gene Editing Market Report Segmentation

6 segment dimensions are covered across the global market.

By Offering

  • Products
  • Services

By Type

  • Cell Line Development & Engineering
  • Gene Editing Kits
  • Gene Editing Libraries
  • Gene Editing Reagents
  • Grna Synthesis & Vector Construction
  • Library Construction & Screening
  • Other Services
  • Reagents & Consumables
  • Software & Systems

By Technique

  • Gene Silencing
  • Knock-In
  • Knock-Out
  • Other Techniques

By Technology

  • Antisense
  • Base Editing
  • Crispr
  • Other Technologies
  • Rnai
  • Talens
  • Zfns

By Application

  • Cell Line Engineering
  • Drug Discovery & Development
  • Genome Editing
  • Other Applications

By End User

  • Academic & Research Institutes
  • Cros & Cdmos
  • Other End Users
  • Pharmaceutical & Biotechnology Companies

Target Audience

  • Biotech & Pharma Companies : Gene editing firms and pharmaceutical companies need Rest Of Latin America market data to identify expansion opportunities, assess market entry feasibility, and develop region-specific commercialization strategies.
  • Healthcare Investors : Private equity and venture capital investors require detailed Rest Of Latin America market insights to evaluate investment returns, identify high-growth opportunities, and assess portfolio diversification in emerging biotech markets.
  • Healthcare Providers & Institutions : Hospitals, research centers, and medical institutions in Rest Of Latin America need market intelligence to plan genetic therapy service offerings, justify technology investments, and align with regional growth trends.
  • Government & Policy Makers : Healthcare regulators and government agencies in Rest Of Latin America require market data to develop supportive policies, allocate healthcare budgets, and foster gene editing innovation ecosystems.
  • Market Research & Consulting Firms : Research organizations and consultants need Rest Of Latin America-specific market data to support client advisory services, competitive analysis, and strategic planning across the gene editing sector.

Key Companies in the Rest Of Latin America Gene Editing Market

CompanyHQOwnershipStrongest segments
EPPENDORF AGGermanyPrivate CompanyLiquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors),
ILLUMINA INCUnited StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
CALYXTUnited StatesPublic CompanyRTDS / Trait Machine platform services,Licensed gene-edited traits (royalties and access fees),Collaborative R&D and proof-of-concept projects,
MAXCYTE, INCUnited StatesPublic CompanyExPERT GTx and VLx (therapeutic-scale instruments),ExPERT STx and ATx (discovery and development instruments),Disposable processing assemblies and consumables,
BECKMAN COULTERUnited StatesPrivate CompanyClinical diagnostics analyzers and reagents (chemistry, immunoassay, hematology, urinalysis, hemostasis, clinical flow cytometry),Research and discovery systems (flow cytometry, centrifugation, liquid handling, genomics and single-cell tools),Industrial and particle characterization instruments,
TAKEDA PHARMACEUTICAL COMPANYJapanPublic CompanyGastroenterology (Entyvio, Takecab/Vocinti, EOHILIA),Rare Diseases & Plasma-Derived Therapies (Takhzyro, Advate, ADZYNMA, Gammagard, Hyqvia, Cuvitru, Flexbumin),Oncology (Adcetris, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, Leuplin/Enantone),
DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and single-use solutions),Life Sciences (tools, genomics, and imaging),Diagnostics (clinical instruments and consumables),
REVVITY, INC.United StatesPublic CompanyDiagnostics assays and instruments (prenatal, neonatal, infectious disease, autoimmunity),Life science reagents and consumables (immunology, cell biology, genomics),Instruments, imaging, and detection platforms,
THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing services),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
GENSCRIPTHong KongPublic CompanyLife Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
LONZASwitzerlandPublic CompanyIntegrated Biologics,Advanced Synthesis (small molecules, ADCs, HPAPIs),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
SANGAMO THERAPEUTICSUnited StatesPublic CompanyHemophilia A gene therapy collaborations (SB-525 / giroctocogene fitelparvovec),Fabry and other AAV gene therapy programs (ST-920 and related),Genetically modified cell therapy (TX200, kidney transplant),
PRECISION BIOSCIENCESUnited StatesPublic CompanyARCUS platform collaborations and licensing,In vivo HBV and liver disease programs (PBGENE-HBV, iECURE-OTC),Neuromuscular and mitochondrial programs (PBGENE-DMD, PBGENE-3243),
CELLECTIS S.A.FrancePublic CompanyAllogeneic CAR-T for hematologic malignancies (BALLI-01, NatHaLi-01, ALPHA3),Gene therapy and non-hematologic oncology (TRAVERSE, Melanoma, other gene-editing programs),Platform technologies, collaborations, and other R&D-related revenue,
REGENERON PHARMACEUTICALS, INC.United StatesPublic CompanyEYLEA franchise (incl. 8 mg),Dupixent (atopic dermatitis, asthma, other type 2 diseases),Oncology (Libtayo and emerging bispecifics),
TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (COVID-19 and related),

EPPENDORF AG

Eppendorf AG is a German private company founded in 1945 that employs 4,358 people. The company specializes in laboratory equipment and life sciences solutions.

ILLUMINA INC

Illumina Inc. is a publicly traded U.S. company founded in 1998 with 8,625 employees. It is a leading provider of DNA sequencing and genetic analysis technologies.

CALYXT

Calyxt is a publicly traded U.S. company founded in 2010 with 118 employees. The company focuses on plant biotechnology and gene-edited crop development.

MAXCYTE, INC

MaxCyte, Inc. is a publicly traded U.S. company founded in 1998 with 91 employees. It develops cell engineering technologies for therapeutic applications.

BECKMAN COULTER

Beckman Coulter is a private U.S. company founded in 1935 with 11,900 employees. It manufactures laboratory instruments and diagnostic equipment for life sciences research.

TAKEDA PHARMACEUTICAL COMPANY

Takeda Pharmaceutical Company is a publicly traded Japanese pharmaceutical company founded in 1781 with 47,029 employees. It is one of the world's largest pharmaceutical manufacturers.

DANAHER CORPORATION

Danaher Corporation is a publicly traded U.S. company founded in 1969 with 59,000 employees. It operates a diversified portfolio of businesses in diagnostics, life sciences, and environmental solutions.

REVVITY, INC.

Revvity, Inc. is a publicly traded U.S. company founded in 1937 with 11,000 employees. It provides analytical technologies and solutions for life sciences and diagnostics.

THERMO FISHER SCIENTIFIC INC.

Thermo Fisher Scientific Inc. is a publicly traded U.S. company founded in 1956 with 125,000 employees. It is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.

MERCK KGAA

Merck KGaA is a publicly traded German company founded in 1668 with 59,077 employees. It operates in pharmaceuticals, life sciences, and performance materials sectors.

GENSCRIPT

GenScript is a publicly traded company based in Hong Kong, founded in 2002 with 6,165 employees. It provides biotechnology services including gene synthesis, protein production, and antibody development.

AGILENT TECHNOLOGIES, INC.

Agilent Technologies, Inc. is a publicly traded U.S. company founded in 1999 with 18,000 employees. It manufactures analytical instruments and laboratory equipment for life sciences and diagnostics.

LONZA

Lonza is a publicly traded Swiss company founded in 1897 with 20,000 employees. It provides contract manufacturing and life sciences solutions for pharmaceuticals and biotechnology.

SANGAMO THERAPEUTICS

Sangamo Therapeutics is a publicly traded U.S. company founded in 1995 with 142 employees. It develops gene therapy and cell therapy treatments using zinc finger protein technology.

PRECISION BIOSCIENCES

Precision Biosciences is a publicly traded U.S. company founded in 2006 with 66 employees. It develops gene-editing therapies using its proprietary genome editing platform.

CELLECTIS S.A.

Cellectis S.A. is a publicly traded French company founded in 1999 with 227 employees. It develops immunotherapy treatments using gene-edited cell technologies.

REGENERON PHARMACEUTICALS, INC.

Regeneron Pharmaceuticals, Inc. is a publicly traded U.S. company founded in 1988 with 15,343 employees. It discovers, develops, and commercializes medicines for serious medical conditions.

TAKARA BIO INC.

Takara Bio Inc. is a private Japanese company founded in 2002 with 1,779 employees. It develops and manufactures biotechnology products and services for life sciences research.

Reasons to Buy this Report

  • Regional Market Sizing : Obtain precise valuation data for Rest Of Latin America's gene editing market with verified 2024 baseline ($34.4M) and 2029 forecasts ($50.6M), enabling accurate investment and expansion planning.
  • Growth Trajectory Analysis : Understand Rest Of Latin America's 8% CAGR performance relative to global 10.2% growth, identifying regional dynamics and market maturation patterns specific to this emerging geography.
  • Competitive Positioning : Benchmark your gene editing portfolio against Rest Of Latin America's market characteristics, identifying entry opportunities and competitive advantages in this underserved but growing region.
  • Investment Decision Support : Make informed capital allocation decisions with comprehensive Rest Of Latin America market intelligence, including growth drivers, healthcare investment trends, and therapeutic adoption patterns.
  • Strategic Expansion Planning : Develop targeted go-to-market strategies for Rest Of Latin America by understanding regional healthcare infrastructure, regulatory environment, and emerging opportunities in genetic therapy applications.

Frequently asked questions

What is the current market size of gene editing in Rest Of Latin America?

Rest Of Latin America's gene editing market was valued at $34.4 million in 2024 and is projected to grow to $50.6 million by 2029.

What is the expected growth rate for gene editing in Rest Of Latin America?

Rest Of Latin America's gene editing market is expected to grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2029.

What are the primary drivers of gene editing market growth in Rest Of Latin America?

Rest Of Latin America's market growth is driven by rising prevalence of genetic disorders, increased healthcare spending, improving regulatory frameworks, and strengthening biotechnology infrastructure.

Which gene-editing technologies are most prevalent in Rest Of Latin America?

Rest Of Latin America is witnessing accelerated adoption of CRISPR and other advanced gene-editing technologies, particularly for therapeutic applications in inherited diseases and cancer treatment.

How is the competitive landscape evolving in Rest Of Latin America's gene editing market?

Rest Of Latin America's competitive environment is becoming increasingly dynamic, with both regional biotechnology companies and international pharmaceutical firms establishing presence to capitalize on emerging opportunities.

RESEARCH METHODOLOGY

This study involved four major activities in estimating the current size of the gene editing market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used primarily to identify and gather information for this extensive, technical, market-oriented, and commercial study. The secondary sources referred to for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global gene editing market, and the findings were validated through primary research.

Primary Research

In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Gene Editing Market 
 Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global gene editing market size was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:

Gene Editing Market Top Down and Bottom Up Approach

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

Market Definition

Gene editing refers to technologies used to modify, insert, delete, or regulate specific DNA sequences in cells and organisms. These technologies enable targeted genetic modifications through approaches such as CRISPR-Cas, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), base editing, and other genome engineering techniques. The gene editing market includes products such as reagents & consumables and software & systems, as well as specialized services such as cell line development & characterization, gRNA synthesis & vector construction, and library construction & screening. These products and services are widely used in cell line engineering, genome editing, drug discovery and development, and genetic research. They also support applications in biotechnology, biopharmaceutical production, and therapeutic development. Rising investment in genetic research, advances in genome-editing technologies, and the growing adoption of precision medicine are driving demand for gene editing products and services across pharmaceutical, biotechnology, and academic research institutions.

Key Stakeholders

  • Academic Research Institutes
  • Raw Materials Manufacturers & Distributors
  • Contract Research Organizations (CROs)
  • Service Providers
  • Market Research and Consulting Firms
  • Pharmaceutical & Biotechnology Companies
  • Regulatory Agencies
  • Venture Capitalists
  • Government Organizations
  • Private Research Firms
  • Contract Development and Manufacturing Organizations (CDMOs)

Report Objectives

  • To define, describe, and forecast the gene editing market by product & service, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall gene editing market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil and the Rest of Latin America), the Middle East (GCC Countries and the Rest of the Middle East), and Africa
  • To profile the key players and analyze their market shares and core competencies
  • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

Available customizations:

Based on the market data, MarketsandMarkets offers customizations to meet the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

  • Further breakdown of the market in the Rest of Europe, by country
  • Further breakdown of the market in the Rest of Asia Pacific, by country

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

  • Cross-segment analysis

 

Get the Full Gene Editing Market Report

Full forecast, segment splits, and company analysis for all Gene Editing Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status